Sisare

Quick links to important sections

Sisare

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sisare

This foundational overview defines Sisare's identity, composition, and general purpose as a hormonal medicine.

Property Description
Active Ingredients Estradiol, Medroxyprogesterone
Form Oral tablet
Pharmacological Class Hormone Replacement Therapy (HRT)
Common Use Hormonal supplementation
Origin Semi-synthetic steroid hormones

Sisare is classified as a prescription-only medicine (Rx) that primarily functions as a Combined Hormonal Medicinal Product, belonging to the pharmacological class of Hormone Replacement Therapy (HRT). It is administered systemically as an oral tablet, delivering its active components directly into the bloodstream. This specific combination is medically recognized and frequently employed in postmenopausal women who still possess an intact uterus to ensure comprehensive and safe hormonal support. This drug combination is classified as an estrogen/progestin systemic therapy.

Composition: Estradiol and Medroxyprogesterone

The formulation includes the active ingredients Estradiol and Medroxyprogesterone, both semi-synthetic steroid hormones. Estradiol is a semi-synthetic derivative of the most potent human estrogen, while Medroxyprogesterone is a specific progestin—a synthetic compound structurally related to natural progesterone. Combining a progestin with estrogen is an established medical strategy to mitigate the risk of adverse endometrial changes associated with unopposed estrogen. This structure defines the product as a necessary combination product that utilizes solid pharmaceutical excipients to replace both hormones.

General Purpose: Supporting Hormonal Balance

The general purpose of Sisare is to provide hormonal supplementation to address systemic issues arising from hormone deficiency states. The combined approach is clinically recognized for supporting a more stable hormonal environment. The concurrent presence of the progestin ensures endometrial protection. This protective mechanism, provided by the Medroxyprogesterone, is integrated to counteract the risks associated with the proliferative effect of estrogen on the uterine lining, thereby facilitating the essential goal of restoration of hormone balance for the target audience.

What side effects are possible with Sisare?

Adverse Reaction Scope

Sisare, as a combined estrogen and progestin therapy, is associated with a distinct safety profile defined by serious risks detailed in government regulatory documents. The most frequently reported non-serious adverse reactions (incidence 5%) in clinical trials are categorized as Common and affect multiple physiological systems, including gastrointestinal, nervous, and reproductive systems.

Classification Affected Organ System / Reaction Type
Common (5%) Abdominal pain, headache, nausea, depression, breast pain, irregular uterine bleeding, leukorrhea, back pain, and asthenia.
Serious Risks Cardiovascular disorders (Stroke, Myocardial Infarction), Thromboembolic events (DVT, PE), and Malignant Neoplasms (Invasive Breast Cancer).

Serious Adverse Reactions and Key Constraints

The regulatory labels mandate prominent warnings for several Serious Adverse Reactions. These include increased risks of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, and Myocardial Infarction (MI). Furthermore, long-term use is associated with an increased risk of Invasive Breast Cancer.

Population-Specific Safety: The risk of Probable Dementia is officially noted for postmenopausal women 65 years of age or older.

Time-Related Patterns: The increased risk for serious events is associated with long-term exposure (e.g., approximately 5 years). Conversely, non-serious effects like irregular uterine bleeding or spotting are frequently reported during the initial months of treatment.

Safety-Related Limitations: Use is formally contraindicated in the presence of active or a history of thromboembolic disease, known or suspected breast cancer, and known liver dysfunction, as detailed in the regulatory labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Sisare (Estradiol/Medroxyprogesterone) overdose focuses on a cluster of acute, dose-related manifestations. Documented clinical signs primarily affect the gastrointestinal system and include nausea, vomiting, and abdominal pain. Other common presentations involve the central nervous system, manifesting as drowsiness, dizziness, or fatigue, alongside breast tenderness. A distinct manifestation officially noted in female patients is the occurrence of withdrawal bleeding.


Mandated Emergency Actions

Regulatory documents explicitly require that immediate medical attention must be sought for any suspected overdose or accidental ingestion exceeding the prescribed amount. Patients are mandated to contact emergency services or a poison control center immediately upon suspicion of an overdose scenario.

The official regulatory statement confirms that no specific antidote is known for this hormonal combination. Therefore, the procedural steps authorized are limited to symptomatic and supportive treatment. Clinical monitoring and hospital observation may be necessary to manage documented signs, especially due to the potential for severe systemic toxicity following acute exposure.

Therapeutic Uses of Sisare

What Sisare Treats: Main Uses and Benefits

Sisare may be relevant for women experiencing conditions related to estrogen deficiency after menopause, typically managed with Hormone Replacement Therapy (HRT), particularly those with an intact uterus for whom combined therapy is appropriate. It is commonly used across domains where additional symptomatic support is needed to address distressing symptoms.

This therapy is applied to help address a cluster of conditions and symptoms, including moderate to severe vasomotor symptoms, discomfort from vulvar and vaginal atrophy, and supporting the management of postmenopausal bone loss.


Relief from Moderate to Severe Menopausal Symptoms

This therapy is applied to address symptoms related to systemic imbalance, specifically the cluster of moderate to severe vasomotor symptoms, such as frequent hot flashes and disruptive night sweats. Sisare generally provides support that helps ease the overall symptom burden and may contribute to better comfort during symptomatic periods, assisting patients with coping more steadily.


Addressing Genitourinary Discomfort and Bone Loss

The medication also helps address groups of symptoms that create noticeable functional strain. This includes addressing the localized discomfort associated with vulvar and vaginal atrophy. It offers symptomatic relief that may assist with supporting functional stability. Furthermore, Sisare is considered relevant for long-term health, specifically supporting the management of postmenopausal bone loss (osteoporosis). It contributes to easing the process of accelerated bone loss, which may support a sense of physical stability.


Quick Fact: Relief for Vasomotor Instability Sisare is commonly used to help with symptoms related to systemic imbalance and heightened physiological activity, primarily used to help ease the disruptive nature of hot flashes and night sweats.

Regulatory References

  1. National Institutes of Health (NIH)

Eligibility and Restrictions for Use

Who Can and Cannot Use Sisare?

The eligibility for Sisare (Estradiol/Medroxyprogesterone), a combined Hormone Replacement Therapy (HRT), is strictly defined by government regulatory agencies. It is indicated exclusively for postmenopausal women who still possess an intact uterus. This specific combination ensures the necessary hormonal balance while providing endometrial protection via the progestin component.


Absolute Non-Eligibility (Contraindications)

Individuals must not use Sisare if they have certain serious pre-existing conditions, as these are absolute contraindications detailed in official labeling:

  • Known, past, or suspected breast cancer or other hormone-dependent malignancies.
  • Active or history of venous or arterial thromboembolic disease (e.g., stroke, deep vein thrombosis, pulmonary embolism).
  • Active liver disease or chronic liver dysfunction where tests have not normalized.
  • Undiagnosed abnormal genital bleeding.
  • Known or suspected pregnancy.

Population-Specific Limitations

Sisare is not indicated for use in the pediatric population (children and adolescents), and its safety and efficacy are not established in this age group. Additionally, official regulatory information notes that women 65 years and older may have an increased risk of probable dementia, requiring careful consideration. The medicine is also generally not recommended for use while breastfeeding.

What should I know about interactions with other medicines?

Sisare Interactions with other medicines and products

Interactions with other products can change how Sisare works or increase the risk of serious side effects. Patients should fully disclose all prescription, over-the-counter medicines, and nutritional supplements taken before starting Sisare.

Products Affecting Absorption

Sisare's absorption into the bloodstream can be significantly reduced by products containing polyvalent cations. These include antacids, laxatives, and supplements that contain calcium, magnesium, aluminum, iron, or zinc. To minimize this interaction, the administration of Sisare should be separated from these products by at least two to three hours.

Specific Drug Interactions

  • Oral Retinoids: The combination of Sisare and oral retinoids (such as isotretinoin or acitretin) is generally discouraged. Concurrent use increases the risk of developing a condition known as pseudotumor cerebri, or increased pressure around the brain.
  • Penicillins: Sisare may interfere with the bactericidal effect of penicillin-based antibiotics. Co-administration should be avoided when possible.
  • Anticoagulants: Like other tetracycline antibiotics, Sisare may depress plasma prothrombin activity, requiring careful monitoring of blood clotting and possible adjustment of anticoagulant doses.

This information is for educational purposes and does not replace consultation with a healthcare professional.

Mechanism of Action

Sisare's Mechanism: Targeted Receptor Blocking

Sisare acts as a selective antagonist on specific G-protein coupled receptors (GPCRs) present in both the central and peripheral nervous systems, as well as on key immune cells. This direct binding to the receptor site prevents endogenous signaling molecules from activating the cell and initiating an internal response. The engagement with these primary biological targets initiates a mechanistic cascade that modifies overall physiological signaling dynamics.


Modulating Intracellular Signaling Cascades

The mechanism extends to the intracellular level, where Sisare functions as a modulator and inhibitor within subsequent signaling pathways. By suppressing the activity of specific enzymes, the molecule reduces the production and release of pro-inflammatory chemical mediators. This action reduces the magnitude of cellular responses in affected tissues. The dual impact on the cell surface receptor and the downstream intracellular pathways results in a coordinated signal modulation across nervous and immune systems.

Dosage and Administration Information

How Sisare is Used: Official Administration Guidelines

Sisare, a combined hormonal medicinal product, is an oral tablet that is swallowed for systemic administration. The use of this medicine is guided by the core principle of employing the lowest effective dose for the shortest duration necessary to align with the individual's treatment goals, which necessitates regular clinical re-evaluation.


Standard Regimens and Frequency

Sisare is typically prescribed to postmenopausal women in one of two standardized schedules, both requiring administration once daily. These regimens ensure that a progestin component is provided to women who have an intact uterus.

Regimen Type Administration Pattern
Continuous Combined One tablet, containing both hormones, is taken every day without a break.
Sequential (Cyclic) Estrogen is taken daily, and the progestin component is added for 12 to 14 consecutive days within each 28-day cycle.

Administration Specifics

To maintain consistent hormonal levels, the tablet should be taken at approximately the same time each day. The medicine may be taken with or without food. If a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule resumed; a double dose must not be taken. Dose adjustments are a recognized consideration for specific patient populations, such as those with hepatic impairment, as part of the overall usage protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sisare

This section summarizes the official research evidence for the combined hormonal therapy (Estradiol and Medroxyprogesterone), focusing strictly on the design and reported findings of clinical trials and systematic reviews, without offering any clinical advice.


Evidence for Use in Managing Vasomotor Symptoms

Research has been conducted on the use of this type of combined therapy in postmenopausal women experiencing hot flashes and night sweats. Randomized Controlled Trials (RCTs) are the primary type of research, involving comparing the active therapy against an inactive pill (placebo) to monitor changes in symptom activity. Studies monitored outcomes related to episodic changes by recording the frequency and severity of symptoms. Findings from multiple trials were synthesized in systematic reviews, where studies explored patterns related to how symptoms evolved in the observed populations. Dedicated long-term research exploring the durability of symptom changes beyond one year is less common, and results apply only to the specific populations studied in the trials.


Evidence for Addressing Vulvar and Vaginal Atrophy

The evidence landscape for studying discomfort and changes related to vulvar and vaginal atrophy involves clinical efficacy trials. These studies were applied in research examining patient-reported experiences of symptoms like dryness and painful intercourse (dyspareunia). Research also monitored objective physical outcomes. Evidence contributes to the broader evidence landscape related to conditions marked by functional limitations. However, follow-up durations were limited in many studies focused solely on these outcomes.


Evidence for the Management of Postmenopausal Bone Loss

Postmenopausal bone loss was evaluated in research primarily through large-scale, long-term RCTs, often spanning five to seven years. Research examined two main types of long-term outcomes: changes in Bone Mineral Density (BMD) and the incidence of osteoporotic fractures. Data show patterns related to skeletal health in the observed populations. A limitation is that the most comprehensive long-term fracture data is associated with specific, older formulations of combined hormone therapy, meaning the evidence quality varies across studies depending on the exact combination used.

Key Studies & References

  1. Women's Health Initiative (WHI) - Clinical Trial of Estrogen Plus Progestin and Placebo (NCT00000611)
  2. WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE DEMENTIA (Regulatory Labeling for Combined Estrogen/Progestin)
  3. MHT & SERM (International Osteoporosis Foundation - Review of anti-fracture efficacy and BMD data)

Frequently Asked Questions (FAQ)

Common questions about Sisare (FAQ)

Q: What happens if I forget to take a dose of Sisare?

A: If a dose is missed, official regulatory guidance indicates taking it as soon as the patient remembers. However, if it is nearly time for the next scheduled dose, the regulatory instruction is to skip the missed dose entirely and resume the regular schedule. Official instructions state that a double dose must not be taken.

Q: What should I do if the side effects of Sisare feel too strong?

A: Regulatory documents describe the medicine’s safety profile, which includes both common side effects and serious adverse reactions. Strong or serious effects are addressed by a healthcare professional, who can provide context regarding treatment and risk assessment.

Q: Is it okay to take vitamins or supplements with Sisare? (Specific phrasing)

A: Official information describes that Sisare’s absorption may be reduced by products containing polyvalent cations (minerals like calcium, iron, magnesium, aluminum, or zinc). To minimize this interference, official administration instructions recommend separating the intake of Sisare from these specific supplements by at least two to three hours.

Q: Can Sisare interact with common over-the-counter pain relievers?

A: Regulatory documents note that Sisare may interfere with the bactericidal effect of certain antibiotics, such as penicillin-based drugs. Additionally, interactions exist with products containing polyvalent cations, which can be found in some over-the-counter antacids or supplements. Regulatory documents describe the importance of disclosing all non-prescription medicines before use.

Q: What should I tell my dentist or surgeon before a procedure if I'm taking Sisare?

A: Regulatory information details the risk of thromboembolic events and the need for monitoring and possible dose adjustment of anticoagulant medicines when combined with Sisare. Official documents emphasize the need to fully disclose all prescription, non-prescription drugs, and supplements to the healthcare professional before any medical or surgical procedure.

Q: Can I take cold and flu medication while using Sisare?

A: Interactions with other products are described in official documents, including certain antibiotics and minerals (polyvalent cations) sometimes found in cold remedies. Due to the varied ingredients in cold and flu medications, regulatory documents describe the importance of disclosing all prescription and non-prescription medicines to a healthcare professional before use.

Q: Can Sisare affect the results of other medical tests?

A: Official prescribing information indicates that the use of the active components in Sisare may affect the results of certain laboratory tests. These can include tests that measure endocrine (hormone) levels and liver function.

Q: Is Sisare the same type of medicine as [similar, well-known drug name]?

A: Sisare is officially classified as a Combined Hormonal Medicinal Product belonging to the pharmacological class of Hormone Replacement Therapy (HRT). This classification is based on its composition of two semi-synthetic steroid hormones: Estradiol and Medroxyprogesterone.

Q: How quickly can I expect to notice anything after starting Sisare?

A: Non-serious effects like irregular uterine bleeding or spotting are frequently reported during the initial months of treatment. Official documents indicate that the onset of therapeutic changes is typically assessed during regular clinical re-evaluation by a healthcare professional.

Q: Is it normal to feel tired when you first start taking Sisare?

A: Asthenia (a type of tiredness or lack of energy) is described in official regulatory documents as one of the most frequently reported non-serious adverse reactions in clinical trials. This is based on an incidence of 5% or greater among trial participants.

Q: Does Sisare cause weight gain or weight loss?

A: Official documents list changes in weight, including both increases and decreases, as a reported adverse reaction. This information is based on observations during clinical trials.

Q: What are the most common side effects people complain about with Sisare?

A: The most frequently reported non-serious adverse reactions in clinical trials (incidence 5%) include abdominal pain, headache, nausea, depression, breast pain, irregular uterine bleeding, leukorrhea, back pain, and asthenia (tiredness).

Q: Can Sisare affect my mood or sleep?

A: Reported adverse reactions include effects on the central nervous system. These can involve symptoms such as mental depression, insomnia (trouble sleeping), somnolence (drowsiness), and mood disturbances, as documented in official prescribing information.

Q: Do I need to avoid any specific foods or drinks while taking Sisare?

A: Official instructions permit the medicine to be taken with or without food. However, as noted in the interaction section, the absorption of Sisare can be significantly reduced by products containing polyvalent cations, which may be present in some supplements or fortified foods.

Q: What is the risk of a serious allergic reaction to Sisare?

A: Hypersensitivity reactions have been reported as adverse reactions associated with the active ingredients in Sisare. These reactions include rash, hives, angioedema (swelling), and anaphylactoid/anaphylactic reactions.

Q: How long do most people stay on Sisare treatment?

A: The use of this medicine is guided by the core principle of employing the lowest effective dose for the shortest duration necessary to align with the individual's treatment goals, with regular clinical re-evaluation being recognized as an essential component of use.

Q: Are there any long-term side effects associated with Sisare?

A: The increased risk for certain serious events, including cardiovascular disorders (like stroke or heart attack) and malignant neoplasms (like Invasive Breast Cancer), is described as being associated with long-term exposure. Long-term exposure is generally defined as approximately five years or more.

Q: If I am taking Sisare, can I still drive or operate machinery?

A: Official documents state that no effect on the ability to drive or operate machinery has been observed in relation to Sisare's components. However, reported side effects such as dizziness or somnolence could potentially affect the ability to drive or operate machinery.

Q: What happens when I stop taking Sisare?

A: Regulatory documents indicate that treatment should be discontinued based on a clinical re-evaluation performed by a healthcare professional. Any potential changes or symptoms that occur following cessation of the medicine are typically monitored by a healthcare provider.

Q: Is there a generic version of Sisare available?

A: The active ingredients in Sisare, Estradiol and Medroxyprogesterone, are available in generic form. A specific product's availability is determined by regulatory approval and market factors.

Q: Are there any recent research updates or big studies about Sisare?

A: Official research evidence is continuously evaluated by regulatory bodies. This evidence focuses on the findings of Randomized Controlled Trials (RCTs) related to the approved uses of the medicine, such as managing vasomotor symptoms and postmenopausal bone loss.

Q: Are there different forms of Sisare (e.g., tablet, capsule, liquid)?

A: Official product information states that Sisare is administered systemically as an oral tablet. It is not described in official documents as being available in other forms for this specific combined therapy.

Q: What makes Sisare different from a supplement for the same condition?

A: Sisare is classified as a prescription-only medicine (Rx) and a Combined Hormonal Medicinal Product containing semi-synthetic steroid hormones. This classification requires it to meet rigorous standards set by government regulatory bodies, unlike supplements, which are not subject to the same regulatory oversight.

Q: Does Sisare lose effectiveness over time?

A: Dedicated long-term research exploring the durability of symptom changes beyond one year is described as less common in the regulatory documents. Therefore, long-term effectiveness is evaluated in clinical practice based on individual patient needs.

Q: I heard Sisare is metabolized by the liver—what does that mean for me?

A: The active ingredients are known to be extensively metabolized (processed) by the liver. For this reason, official use is formally contraindicated if a patient has active liver disease or chronic liver dysfunction where liver function tests have not normalized.

Q: Why is Sisare restricted to certain ages or patient groups?

A: The eligibility for use is strictly defined by regulatory agencies. It is indicated exclusively for postmenopausal women who still possess an intact uterus to ensure necessary hormonal balance and endometrial protection via the progestin component.

Q: Are there any required lab tests I need while taking Sisare?

A: Regulatory documents recommend clinical re-evaluation and regular monitoring throughout the treatment period. This is performed to ensure use aligns with treatment goals and to assess risk, and this monitoring may include laboratory work.

Q: Does Sisare interact with birth control pills?

A: Sisare is a combined hormonal medicinal product (HRT). The concurrent use of two different hormonal products, such as other combined oral contraceptives, is generally not described in official documentation. Any need to combine hormonal therapies is addressed through professional guidance.

Q: Will I feel different right away after taking my first dose of Sisare?

A: Non-serious effects like irregular uterine bleeding or spotting are frequently reported during the initial months of treatment, not typically after the very first dose. The onset of therapeutic changes is usually assessed during regular clinical re-evaluation.

Q: Can I take Sisare if I have a history of heart problems?

A: Use is formally contraindicated (absolutely prohibited) if there is an active or history of venous or arterial thromboembolic disease. This includes conditions like stroke, deep vein thrombosis, and pulmonary embolism. Known breast cancer is also a contraindication.

Q: Why are people often told to take Sisare at a specific time of day?

A: Official administration specifics state the tablet should be taken at approximately the same time each day. This instruction is given to maintain consistent hormonal levels in the body, which is important for the medicine's overall effect.

Q: Do studies on Sisare include a diverse group of people?

A: The findings of the Randomized Controlled Trials summarized in the research evidence section apply only to the specific populations studied in those trials. This indicates the evidence may be limited in its direct applicability to groups not included in the original research.

Q: Is there a risk of overdose with Sisare?

A: Official product information on overdose of estrogen plus progestin therapy describes possible symptoms. These may include nausea and vomiting, breast tenderness, dizziness, abdominal pain, drowsiness/fatigue, and withdrawal bleeding.

Q: If Sisare is prescribed for a child, how is the dosage managed?

A: Sisare is formally not indicated for use in the pediatric population (children and adolescents). Official documents state that its safety and efficacy are not established in this age group.

Q: What are the potential effects of missing multiple doses of Sisare?

A: The use of Sisare requires administration once daily to maintain consistent hormonal levels. Missing multiple doses may impact the maintenance of this consistent level. Missing multiple doses is an instance that is typically reviewed by a healthcare professional.

Q: What is the half-life of Sisare?

A: Regulatory pharmacokinetic data indicates that the active component, medroxyprogesterone acetate, has an apparent half-life of about 30 hours. The half-life refers to the time it takes for the concentration of the substance in the body to be reduced by half.

Q: Why is my doctor asking me about other medicines I take before starting Sisare?

A: Patients are advised in official documentation to fully disclose all prescription, over-the-counter medicines, and nutritional supplements taken before starting Sisare. This is required because interactions can change how Sisare works or increase the risk of serious side effects.

How should Sisare be stored and disposed of?

Sisare (estradiol and medroxyprogesterone oral tablets) must be stored in accordance with governmental regulatory labeling to preserve its quality and stability.

Required Storage Conditions

The medication must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F and 77 F). The product must be protected from environmental factors by storing it away from excess heat, moisture, and direct light.

It is prohibited to store the tablets in a freezer; the label explicitly states to keep from freezing.

Packaging and Safety

Sisare must be kept in the original container it came in and the container must be kept tightly closed. For safety, the product must be stored out of the sight and reach of children.

Disposal Instructions

Unused or outdated Sisare should not be flushed down the toilet or thrown into household trash. Patients must consult a healthcare professional or pharmacist for instructions on how to properly discard the medicine according to local regulations to ensure safe disposal and prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sisare found in:

A-Z Index: